华润双鹤：安徽双鹤氯化钾注射液获得药品补充申请批准通知书

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., has received the approval notice for the supplementary application of potassium chloride injection from the National Medical Products Administration. This product is used for the treatment and prevention of hypokalemia, particularly when oral potassium supplementation is not feasible [1]. Company Summary - The approval for potassium chloride injection marks a significant milestone for Anhui Double Crane Pharmaceutical, enhancing its product portfolio in the pharmaceutical market [1]. - The total R&D investment for potassium chloride injection by Anhui Double Crane has reached 1.6109 million RMB (approximately 0.161 million USD) as of the date of the announcement [1]. Industry Summary - The potassium chloride injection is critical for addressing hypokalemia, a condition that can arise in various clinical settings, indicating a steady demand for such pharmaceutical products in the healthcare industry [1].